Warm autoimmune hemolytic anemia (wAIHA): cross-border specialty drug access for international patients

Quick orientation

Warm autoimmune hemolytic anemia affects an estimated 1 to 3 per 100,000 people. Idiopathic and secondary forms (post-infection, post-medication, associated with other autoimmune disease) both occur.

Typical age of onset. All ages; commonly diagnosed in adulthood.

Severity tiers. Severity ranges from compensated hemolysis to life-threatening anemia.

Why specialty drugs for Warm autoimmune hemolytic anemia (wAIHA) are hard to access internationally

First-line therapy includes steroids and rituximab; second and third lines have historically been limited. Newer FDA approvals for warm AIHA-specific therapy are emerging.

Treatments approved by the FDA

• Rituxan (rituximab) — FDA approval: 1997 (off-label and indication-specific use). Mechanism: Anti-CD20 monoclonal antibody. Route: Intravenous infusion weekly for 4 weeks. US WAC ballpark: Approximately USD 8,000 to 12,000 per dose.
• Fabhalta (iptacopan) — FDA approval: 2023. Mechanism: Complement factor B inhibitor (paroxysmal nocturnal hemoglobinuria and IgA nephropathy labels; adjacent complement biology). Route: Oral twice daily. US WAC ballpark: Approximately USD 280,000 per year. Country pricing: UAE · Saudi Arabia · India · Egypt · Bahrain · Oman.
• Piasky (crovalimab) — FDA approval: 2024. Mechanism: Complement C5 inhibitor (PNH label; adjacent complement biology). Route: Subcutaneous injection every 4 weeks. US WAC ballpark: Approximately USD 350,000 per year. Country pricing: Qatar · Kuwait · Bahrain · Oman · Lebanon.

Cross-border pathways used for Warm autoimmune hemolytic anemia (wAIHA)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm wAIHA diagnosis by direct antiglobulin test (DAT) and hemolysis markers.
• Exclude secondary causes (medications, infections, other autoimmune disease).
• Document prior therapy and response.
• Hematologist co-management is essential.
• Vaccination updates before complement-targeted therapy.

Common questions

Are complement inhibitors approved for wAIHA?

Approved labels are for related conditions; some are used off-label for refractory wAIHA under specialist guidance.

Are these drugs available locally?

Registration varies by drug and country. We confirm by destination.

Can multiple therapies be combined?

Sequential use is more common than combinations. Your hematologist guides.

How long does shipment take?

Five to fifteen business days from prescription receipt.

What documents are required?

Hematologist's prescription, DAT result, hemolysis workup, and treatment history.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Warm autoimmune hemolytic anemia (wAIHA), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Warm autoimmune hemolytic anemia (wAIHA)

Reserved for you.